Smith Group Asset Management’s AnaptysBio ANAB Stock Holding History

Smith Group Asset Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-630	Closed	-$36K	–	380
2019 Q2	$36K	Hold	630	–	–	﹤0.01%	295
2019 Q1	$46K	Sell	630 -1,700	-73%	-$117K	﹤0.01%	300
2018 Q4	$149K	Buy	+2,330	New	+$173K	0.01%	261
2018 Q3	–	Sell	-2,330	Closed	-$166K	–	428
2018 Q2	$166K	Hold	2,330	–	–	﹤0.01%	259
2018 Q1	$243K	Buy	+2,330	New	+$263K	0.01%	231

Other funds holding ANAB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Smith Group Asset Management's ANAB Position: Q3 2019 in Review

Smith Group Asset Management sold out of AnaptysBio (ANAB) in Q3 2019, closing a stake of 630 shares — an estimated $36K sold.

Smith Group Asset Management first reported a position in ANAB in Q1 2018 and held it in 5 quarters. The position peaked at $243K in Q1 2018. 119 funds tracked by Wall St. Rank hold ANAB as of Q3 2019.

Smith Group Asset Management reported no remaining AnaptysBio position as of Q3 2019 after selling out during the quarter.
Smith Group Asset Management sold 630 AnaptysBio shares in Q3 2019, an estimated $36K.
Smith Group Asset Management first reported a position in AnaptysBio in Q1 2018 and held it in 5 quarters.
Smith Group Asset Management's AnaptysBio position peaked at $243K in Q1 2018.
119 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2019.

Based on Smith Group Asset Management's 13F filing for Q3 2019, filed 12 Nov 2019.